Michael Barbella, Managing Editor07.18.23
Loci Orthopaedics has named Barry Russell as its new CEO. Dr. Brendan Boland is now executive chairperson, succeeding Dr. John O’Shaughnessy, who retired as chair but remains on the company’s Board of Directors.
“The company is moving into an exciting new phase as we add additional team members, new funding, and as we develop our commercialisation plan," Boland said. "It is a huge win for the company to have a talented and proven leader such as Barry joins the team to accelerate the company to the next major milestones”.
Russell has more than two decades of experience in medical device development, international commercialization, and leadership. Russell has had prior roles with increasing seniority at companies such as Boston Scientific Corp. and J&J, before he founded and led his own company, neoSurgical Ltd., through U.S. Food and Drug Administration regulatory clearance, U.S. commercialization, and ultimately to acquisition.
Loci Orthopaedics is developing medical technologies to meet large unmet clinical needs in the orthopedics space. The company focuses on the extremities market segment and has one of the fastest-growing IP portfolios of any company in this area. Recent equity funding approval by the European Investment Bank will add to the company’s current Series A funding round.
“The company’s primary product is for the treatment of thumb base joint arthritis," Russell stated. "The prevalence of this condition is similar to that of hip and knee arthritis, yet the treatment options appear to be decades behind. So, it is truly exciting to be bringing a really novel, evidence-based treatment option to this huge potential market that has the key ingredients to be a paradigm shift in clinical management of this common but very disabling condition”.
Loci Orthopaedics and the InDx device originated from the BioInnovate program, a structured medical device innovation program in Ireland with proven outcomes. Loci Orthopaedics is based at the Business Innovation Centre in the National University of Ireland Galway.
“The company is moving into an exciting new phase as we add additional team members, new funding, and as we develop our commercialisation plan," Boland said. "It is a huge win for the company to have a talented and proven leader such as Barry joins the team to accelerate the company to the next major milestones”.
Russell has more than two decades of experience in medical device development, international commercialization, and leadership. Russell has had prior roles with increasing seniority at companies such as Boston Scientific Corp. and J&J, before he founded and led his own company, neoSurgical Ltd., through U.S. Food and Drug Administration regulatory clearance, U.S. commercialization, and ultimately to acquisition.
Loci Orthopaedics is developing medical technologies to meet large unmet clinical needs in the orthopedics space. The company focuses on the extremities market segment and has one of the fastest-growing IP portfolios of any company in this area. Recent equity funding approval by the European Investment Bank will add to the company’s current Series A funding round.
“The company’s primary product is for the treatment of thumb base joint arthritis," Russell stated. "The prevalence of this condition is similar to that of hip and knee arthritis, yet the treatment options appear to be decades behind. So, it is truly exciting to be bringing a really novel, evidence-based treatment option to this huge potential market that has the key ingredients to be a paradigm shift in clinical management of this common but very disabling condition”.
Loci Orthopaedics and the InDx device originated from the BioInnovate program, a structured medical device innovation program in Ireland with proven outcomes. Loci Orthopaedics is based at the Business Innovation Centre in the National University of Ireland Galway.